Iberdomide Maintenance Therapy in Patients With Multiple Myeloma
Status:
Not yet recruiting
Trial end date:
2030-12-01
Target enrollment:
Participant gender:
Summary
This is a phase II study to determine the feasibility, safety and efficacy of iberdomide
maintenance therapy post-ASCT. Iberdomide will be dosed at 1.0 mg PO daily for days 1-21 of a
28-day cycle. Treatment will continue until disease progression or toxicity. A maximum of 38
subjects will be enrolled. The results from this study will inform the feasibility of
pursuing a phase 3 study comparing iberdomide to lenalidomide maintenance post-ASCT.